Do analysts recommend ADXS or QNRX?

Quoin Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 347.43%. Given Quoin Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is ADXS or QNRX more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Quoin Pharmaceuticals N/A -489.57% -221.17%

Which has stronger valuation & earnings, MIRA or QNRX?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$25.18 N/A

Is MIRA or QNRX more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -106.95% -104.18% Quoin Pharmaceuticals N/A -489.57% -221.17%

Do analysts prefer TAOX or QNRX?

Quoin Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 347.43%. Given Quoin Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings & valuation, LONA or QNRX?

Athira Pharma is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$4.21 N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$25.18 N/A

Is LONA or QNRX more profitable?

Athira Pharma's return on equity of -411.58% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Quoin Pharmaceuticals N/A -489.57% -221.17%

Which has better earnings and valuation, NNVC or QNRX?

NanoViricides is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.40 N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$25.18 N/A

Is NNVC or QNRX more profitable?

NanoViricides' return on equity of -87.90% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Quoin Pharmaceuticals N/A -489.57% -221.17%

Quoin Pharmaceuticals (QNRX) Competitors

$4.47 -0.25 (-5.30%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.50 +0.03 (+0.67%)

As of 10/2/2026 07:41 PM Eastern

Compare

QNRX vs. ADXS, MIRA, TAOX, LONA, and NNVC

Should you buy Quoin Pharmaceuticals stock or one of its competitors? Quoin Pharmaceuticals's main competitors and comparable companies include Ayala Pharmaceuticals (ADXS), MIRA Pharmaceuticals (MIRA), Synaptogenix (TAOX), Athira Pharma (LONA), and NanoViricides (NNVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Quoin Pharmaceuticals compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Quoin Pharmaceuticals has lower revenue, but higher earnings than Ayala Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

Ayala Pharmaceuticals' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

In the previous week, Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Quoin Pharmaceuticals	Neutral

Quoin Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 347.43%. Given Quoin Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Ayala Pharmaceuticals and Quoin Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

MIRA Pharmaceuticals' return on equity of -106.95% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

MIRA Pharmaceuticals currently has a consensus price target of $3.50, indicating a potential upside of 379.39%. Quoin Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 347.43%. Given MIRA Pharmaceuticals' higher probable upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MIRA Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 2 mentions for MIRA Pharmaceuticals and 0 mentions for Quoin Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.98 beat Quoin Pharmaceuticals' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Positive
Quoin Pharmaceuticals	Neutral

Summary

MIRA Pharmaceuticals beats Quoin Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Quoin Pharmaceuticals has lower revenue, but higher earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	109.96	-$28.74M	-$3.85	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Quoin Pharmaceuticals	Neutral

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Synaptogenix has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

Quoin Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 347.43%. Given Quoin Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Quoin Pharmaceuticals has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

Summary

Quoin Pharmaceuticals beats Synaptogenix on 7 of the 13 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Athira Pharma is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

Athira Pharma currently has a consensus target price of $17.33, suggesting a potential upside of 259.61%. Quoin Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 347.43%. Given Quoin Pharmaceuticals' higher possible upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Athira Pharma had 2 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 2 mentions for Athira Pharma and 0 mentions for Quoin Pharmaceuticals. Athira Pharma's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Quoin Pharmaceuticals	Neutral

Athira Pharma has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Athira Pharma's return on equity of -411.58% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

Summary

Athira Pharma beats Quoin Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

NanoViricides' return on equity of -87.90% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

NanoViricides presently has a consensus price target of $6.00, indicating a potential upside of 368.75%. Quoin Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 347.43%. Given NanoViricides' stronger consensus rating and higher probable upside, research analysts clearly believe NanoViricides is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, NanoViricides had 1 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for Quoin Pharmaceuticals. NanoViricides' average media sentiment score of 0.20 beat Quoin Pharmaceuticals' score of 0.00 indicating that NanoViricides is being referred to more favorably in the media.

Company	Overall Sentiment
NanoViricides	Neutral
Quoin Pharmaceuticals	Neutral

NanoViricides is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.40	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by company insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NanoViricides has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Summary

NanoViricides beats Quoin Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Get Quoin Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNRX vs. The Competition

Export

Metric	Quoin Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.98M	$12.28B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	-0.18	802.26	274.71	26.04
Price / Sales	N/A	940.01	656.46	105.13
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	0.29	10.52	10.93	6.31
Net Income	-$15.81M	$2.86B	$3.51B	$362.16M
7 Day Performance	-30.48%	-1.58%	-2.00%	-1.66%
1 Month Performance	-38.43%	-5.55%	-6.19%	-4.68%
1 Year Performance	-37.92%	-2.19%	8.03%	1.57%

Quoin Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNRX Quoin Pharmaceuticals	3.5689 of 5 stars	$4.47 -5.3%	$20.00 +347.4%	-37.9%	$8.98M	N/A	N/A	6
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
MIRA MIRA Pharmaceuticals	2.5131 of 5 stars	$0.84 -3.1%	$3.50 +314.3%	-45.9%	$35.50M	N/A	N/A	2	News Coverage
TAOX Synaptogenix	0.0564 of 5 stars	$4.53 +4.9%	N/A	-31.2%	$33.90M	$772.50K	N/A	4	News Coverage Analyst Downgrade
LONA Athira Pharma	2.9653 of 5 stars	$3.57 +1.7%	$17.33 +385.5%	N/A	$33.54M	N/A	N/A	19	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNRX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. ADXS, MIRA, TAOX, LONA, and NNVC

How does Quoin Pharmaceuticals compare to Ayala Pharmaceuticals?

Summary

How does Quoin Pharmaceuticals compare to MIRA Pharmaceuticals?

Summary

How does Quoin Pharmaceuticals compare to Synaptogenix?

Summary

How does Quoin Pharmaceuticals compare to Athira Pharma?

Summary

How does Quoin Pharmaceuticals compare to NanoViricides?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. ADXS, MIRA, TAOX, LONA, and NNVC

How does Quoin Pharmaceuticals compare to Ayala Pharmaceuticals?

Do institutionals and insiders believe in ADXS or QNRX?

Which has more risk & volatility, ADXS or QNRX?

Which has better earnings and valuation, ADXS or QNRX?

Is ADXS or QNRX more profitable?

Does the media favor ADXS or QNRX?

Do analysts recommend ADXS or QNRX?

Summary

How does Quoin Pharmaceuticals compare to MIRA Pharmaceuticals?

Is MIRA or QNRX more profitable?

Do analysts prefer MIRA or QNRX?

Do insiders and institutionals have more ownership in MIRA or QNRX?

Which has more volatility & risk, MIRA or QNRX?

Which has stronger valuation & earnings, MIRA or QNRX?

Does the media prefer MIRA or QNRX?

Summary

How does Quoin Pharmaceuticals compare to Synaptogenix?

Which has higher valuation and earnings, TAOX or QNRX?

Does the media refer more to TAOX or QNRX?

Do institutionals and insiders have more ownership in TAOX or QNRX?

Which has more volatility & risk, TAOX or QNRX?

Do analysts prefer TAOX or QNRX?

Is TAOX or QNRX more profitable?

Summary

How does Quoin Pharmaceuticals compare to Athira Pharma?

Which has better earnings & valuation, LONA or QNRX?

Do analysts recommend LONA or QNRX?

Does the media refer more to LONA or QNRX?

Which has more volatility and risk, LONA or QNRX?

Do institutionals & insiders have more ownership in LONA or QNRX?

Is LONA or QNRX more profitable?

Summary

How does Quoin Pharmaceuticals compare to NanoViricides?

Is NNVC or QNRX more profitable?

Do analysts prefer NNVC or QNRX?

Does the media refer more to NNVC or QNRX?

Which has better earnings and valuation, NNVC or QNRX?

Do insiders and institutionals believe in NNVC or QNRX?

Which has more volatility & risk, NNVC or QNRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools